STML Stemline Therapeutics Inc.

6.58
0  0%
Previous Close 6.58
Open
Price To Book 1.88
Market Cap 330,101,612
Shares 50,129,326
Volume 54
Short Ratio
Av. Daily Volume 808,831
Stock charts supplied by TradingView

NewsSee all news

  1. Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

    NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today

  2. Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  3. Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

    NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  4. Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today

  5. Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 updated data due 4Q 2020.
SL-401 (Elzonris)
Myelofibrosis (MF)
FDA approval announced December 21, 2018.
SL-401 (Elzonris)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 trial ongoing.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 data due 2020.
SL-401 (Elzonris)
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)
Phase 1 data presented at ESMO September 28, 2019. SD noted in 11 patients.
SL-801
Solid tumors
Phase 2 Stage 3a data due 4Q 2020.
SL-401 (Elzonris)
Chronic myelomonocytic leukemia (CMML) - cancer

Latest News

  1. Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

    NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today

  2. Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  3. Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

    NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  4. Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today

  5. Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  6. Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference

    NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today

  7. Stemline Therapeutics Reports Third Quarter 2019 Financial Results

    Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for tomorrow, Friday November

  8. Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  9. Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019

    NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  10. Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

    NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  11. Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  12. Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

    NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  13. Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,

  14. Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,